Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Related Research units
Abstract
Intrinsic resistance in metastatic renal cell carcinoma (mRCC) was recently associated with poor overall survival (OS), suggesting that VEGF inhibitor sensitivity may represent a valuable prognostic marker. We explored the duration of progression free survival (PFS) in first-line treatment and other variables as prognostic markers in mRCC.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 7 |
| ISSN | 0959-8049 |
| Publication status | Published - 2012 |
| pubmed | 22436979 |
|---|
